drugset / Trial / NCT00824356

Allergen Challenge Chamber Study With Single Dose Intranasal GSK1004723 Compared With Placebo

NCT00824356

Phase 2 Completed 54 enrolled GlaxoSmithKline
RandomizedCrossoverTriple-blindTreatment

Summary

This is a placebo-controlled, 3-period crossover study to assess the efficacy and safety of two single doses of an intranasal anti-histamine GSK1004723 compared with placebo in an allergen challenge chamber in male subjects with seasonal allergic

Timeline

Start
2008-06
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator GSK1004723 Small molecule 200 mg Intranasal
Comparator GSK1004723 Small molecule 1000 mg Intranasal

Indications